Sandeep Shori, DO
Nephrology · Fort Worth, TXNPI 1790727329
Payments from drug & device makers
Across 545 payments — averaging $357.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$57K
- Fresenius USA Marketing, Inc.$50K
- Boehringer Ingelheim$32K
- Lilly USA, LLC$22K
- Amgen$18K
- AstraZeneca$14K
- plus $3K from 31 others
What the payments were for
- Consulting fees$4,0002%
- Speaking & faculty fees$172,22988%
- Travel & lodging$8,0284%
- Food & beverage$10,4625%
- Education$1930%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 84 | $56,774 |
| Fresenius USA Marketing, Inc. | 97 | $49,625 |
| Boehringer Ingelheim | 32 | $32,020 |
| Lilly USA, LLC | 27 | $21,575 |
| Amgen(2 entities) | 83 | $18,149 |
| AstraZeneca(2 entities) | 100 | $13,757 |
| Calliditas Therapeutics US Inc. | 13 | $299 |
| Mallinckrodt Hospital Products Inc. | 11 | $298 |
| Travere Therapeutics, Inc. | 14 | $290 |
| Vifor Pharma, Inc. | 11 | $234 |
| Daiichi Sankyo Inc. | 14 | $234 |
| Novartis | 8 | $230 |
| Baxter Healthcare | 3 | $166 |
| Medtronic | 1 | $152 |
| Nuwellis, Inc. | 1 | $150 |
| GSK | 7 | $129 |
| Otsuka America Pharmaceutical, Inc. | 4 | $93 |
| ANI Pharmaceuticals, Inc. | 4 | $90 |
| Novo Nordisk | 5 | $86 |
| OPKO Pharmaceuticals, LLC | 4 | $78 |
| Scpharmaceuticals Inc. | 4 | $67 |
| Mallinckrodt Enterprises LLC | 2 | $59 |
| Alnylam Pharmaceuticals Inc. | 2 | $43 |
| Cormedix Inc. | 1 | $33 |
| Ardelyx, Inc. | 1 | $31 |
| Abiomed | 1 | $27 |
| Eisai Inc. | 1 | $26 |
| Akebia Therapeutics Inc | 1 | $25 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $24 |
| Recor Medical Inc | 1 | $22 |
| Dexcom, Inc. | 1 | $21 |
| Amicus Therapeutics, Inc. | 1 | $21 |
| Sanofi | 1 | $19 |
| Abbott | 1 | $19 |
| Chiesi USA, Inc. | 1 | $18 |
| Renalytix AI, Inc. | 1 | $15 |
| Ultragenyx Pharmaceutical Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Kerendia$53,066
- JARDIANCE$52,900
- Velphoro$44,962
- Parsabiv$16,484
- LOKELMA$11,750
- Critline - Monitors$3,167
- FARXIGA$200
- CoreValve Evolut$152
- AQUADEX SMARTFLOW CONSOLE$150
- Renal - Acute$123
How this compares
$194,912 in reported general payments places this provider in the 90th percentile of 1,070 nephrology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VelphoroSucroferric Oxyhydroxide | 40 | $119,410 |
| KerendiaFinerenone | 80 | $94,587 |
| JardianceEmpagliflozin | 43 | $29,617 |
| LokelmaSodium Zirconium Cyclosilicate | 12 | $17,221 |
| Cinacalcet Hcl | 25 | $5,352 |
| Sevelamer Carbonate | 42 | $5,198 |
| Nifedipine ErNifedipine | 45 | $1,501 |
| Potassium Chloride | 56 | $1,261 |
| Torsemide | 22 | $1,096 |
| Hydralazine Hcl | 33 | $1,076 |
| Furosemide | 94 | $738 |
| Tamsulosin Hcl | 22 | $329 |
| Calcitriol | 19 | $312 |
| Losartan Potassium | 24 | $300 |
| Amlodipine Besylate | 55 | $259 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Fresenius USA Marketing, Inc.Velphoro | $49,625 | $119,41040 claims |
| BayerKerendia | $56,774 | $94,58780 claims |
| Boehringer IngelheimJardiance | $32,020 | $29,61743 claims |
| AstraZenecaLokelma | $13,757 | $17,22112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,070 nephrology providers in Texas.
Other nephrology in Fort Worth
- Bernard FischbachFort Worth$870K
- Saravanan BalamuthusamyFort Worth$707K
- Pablo PergolaSan Antonio$14.2M
- German HernandezEl Paso$9.7M
- Sreedhar MandayamHouston$7M
- Tahira AlvesSan Antonio$6.1M
- Carl DukesSan Antonio$5.9M
- Chinonye Ogbonnaya-OdorSan Antonio$4.6M
- Marializa BernardoHouston$4.2M
- Judith BettsAustin$3.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.